PRA Health Sciences ( NASDAQ:PRAH ) and Protalex ( OTCMKTS:PRTX ) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.
This table compares PRA Health Sciences and Protalex’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets PRA Health Sciences 2.37% 25.75% 7.48% Protalex N/A N/A -683.38% Analyst Ratings
This is a breakdown of current ratings for PRA Health Sciences and Protalex, as provided by MarketBeat.com. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PRA Health Sciences 0 2 6 0 2.75 PRA Health Sciences currently has a consensus price target of $113.50, suggesting a potential upside of 1.35%. Given PRA Health Sciences’ higher probable upside, equities analysts clearly believe PRA Health Sciences is more favorable than Protalex.
Institutional & Insider Ownership
100.0% of PRA Health Sciences shares are held by institutional investors. Comparatively, 0.2% of Protalex shares are held by institutional investors. 0.9% of PRA Health Sciences shares are held by company insiders. Comparatively, 80.0% of Protalex shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares PRA Health Sciences and Protalex’s top-line revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PRA Health Sciences $2.26 billion 3.22 $86.92 million $3.20 35.00 Protalex N/A N/A -$5.03 million N/A N/A PRA Health Sciences has higher revenue and earnings than Protalex.
Volatility and Risk
PRA Health Sciences has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Protalex has a beta of -0.51, meaning that its share price is 151% less volatile than the S&P 500.
PRA Health Sciences beats Protalex on 9 of the 10 factors compared between the two stocks.
PRA Health Sciences Company Profile PRA Health Sciences logo PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, and bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include targeting and compensation services, and pharmaceutical audit suite; brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services. The company conducts clinical trials in the areas of pharmaceutical development, including oncology, central nervous system, inflammation, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.
Protalex Company Profile Protalex logo Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.
Receive News & Ratings for PRA Health Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for PRA Health Sciences and related companies with MarketBeat.com’s FREE daily email newsletter .
Click here to view original web page at PRA Health Sciences (PRAH) & Protalex (PRTX) Financial Contrast